The Mesoblast limited (ASX:MSB) share price is surging higher on Monday. Here’s why investors are buying its shares…
The post Why the Mesoblast (ASX:MSB) share price is surging 8% higher today appeared first on Motley Fool Australia. –
The Mesoblast limited (ASX: MSB) share price has been a very strong performer on Monday.
In afternoon trade the allogeneic cellular medicines developer’s shares are surging over 8% higher to $5.32.
This leaves the Mesoblast share price trading within sight of its record high of $5.43.
Why is the Mesoblast share price surging higher today?
Investors have been scrambling to buy the company’s shares on Monday ahead of a major announcement later this week.
Last month Mesoblast had a meeting with the Oncologic Drugs Advisory Committee (ODAC) of the United States Food and Drug Administration (FDA).
That meeting was to discuss its remestemcel-L (RYONCIL) product candidate as a treatment for paediatric steroid-resistance acute graft versus host disease (paediatric SR-aGvHD).
Positively for Mesoblast, the ODAC voted overwhelmingly in favour that the available data supports the efficacy of remestemcel-L in paediatric patients with SR-aGvHD.
This is important as the ODAC plays a big role in whether certain drugs get approval or not. Failure to gain the support of the ODAC would make it close to impossible to then gain FDA approval.
So with the ODAC in favour of RYONCIL, the company stands a good chance of gaining approval when the FDA reviews it on Wednesday (United States time).
If it gains approval, then it could be a very lucrative product for Mesoblast. At present there is no FDA-approved treatment options. As such, RYONCIL has the potential to fill a significant unmet medical need.
Should you invest?
Based on its current valuation, I suspect the market is pricing in a reasonably high probability that the company will be granted approval by the FDA.
In light of this, I wouldn’t be in a rush to invest in Mesoblast’s shares at this point.
But it certainly will be worth keeping a close eye on its progress. Especially given the other potential treatments it has in the works.
These certainly are exciting times for shareholders, but I’m just not overly excited about the current share price.
Man who said buy Kogan shares at $3.63 says buy these 3 ASX stocks now
When investing expert Scott Phillips has a stock tip, it can pay to listen. After all, the flagship Motley Fool Share Advisor newsletter he has run for more than eight years has provided thousands of paying members with stock picks that have doubled, tripled or even more.*
In this FREE STOCK REPORT, Scott just revealed what he believes are the 3 ASX stocks for the post COVID world that investors should buy right now while they still can. These stocks are trading at dirt-cheap prices and Scott thinks these could really go gangbusters as we move into ‘the new normal’.
*Returns as of 6/8/2020
- 5 things to watch on the ASX 200 next week
- Why Mesoblast (ASX:MSB) and this ASX 200 share have doubled in value in 2020
- Are biotech shares like Polynovo (ASX:PNV) a better buy than Afterpay?
- ASX 200 falls slightly, miners surge higher
- The Mesoblast (ASX:MSB) share price surges on award win
Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.